PPARGC1A and metabolic dysfunction-associated steatotic liver disease: Deregulation and decrease in the PGC-1α expression itself have also been linked strongly to trigger various metabolic disorders, including obesity, cardiovascular diseases, and NAFLD that cause various inflammatory processes with dysfunctional redox control; therefore, PGC-1α modulation is significant to provide clinical metabolic benefits (47, 48) potentially.